Novavax (XSWX:NVAX) Beginning Cash Position: CHF186.2 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:NVAX Novavax Inc XSWX:NVAX
46 GF Score
Price CHF7.24
GF Value CHF2.58
! 6 Warning Signs
View Full Analysis

What is Novavax Beginning Cash Position?

Novavax XSWX:NVAX +9.21% 46 Beginning Cash Position is CHF186.2 Mil as of Jun. 2026. GuruFocus rates XSWX:NVAX with a GF Score™ of 46/100 and a GF Value™ of CHF2.58. The stock has 6 warning signs investors should review.

Novavax's Beginning Cash Position for the quarter that ended in Jun. 2026 was CHF186.2 Mil.

Novavax's quarterly Beginning Cash Position declined from Dec. 2025 (CHF225.8 Mil) to Mar. 2026 (CHF201.6 Mil) and declined from Mar. 2026 (CHF201.6 Mil) to Jun. 2026 (CHF186.2 Mil).

Novavax's annual Beginning Cash Position declined from Dec. 2023 (CHF1,166.5 Mil) to Dec. 2024 (CHF520.5 Mil) and declined from Dec. 2024 (CHF520.5 Mil) to Dec. 2025 (CHF434.5 Mil).

Novavax Beginning Cash Position Related Terms

Novavax Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Novavax's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Beginning Cash Position Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 597.49 1,423.73 1,166.48 520.52 434.54

Novavax Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 226.46 214.14 225.81 201.59 186.18
XSWX:NVAX
46GF Score
Novavax Inc XSWX:NVAX
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of CHF186.2 Mil mean?
Novavax (XSWX:NVAX) has a Beginning Cash Position of CHF186.2 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Novavax and its competitors.
Is Novavax's Beginning Cash Position too high?
Novavax's current Beginning Cash Position is CHF186.2 Mil. Overall, Novavax has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Novavax's Beginning Cash Position compare to JBIO and AVLN?
Novavax's Beginning Cash Position of CHF186.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Novavax and its competitors. Novavax's current Beginning Cash Position is CHF186.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Novavax (XSWX:NVAX) has a current Beginning Cash Position of CHF186.2 Mil. The stock's GF Value™ is CHF2.58, compared to a current price of CHF7.24 — trading 180.7% above its estimated fair value. The current Beginning Cash Position is CHF186.2 Mil. Novavax's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Novavax (XSWX:NVAX), the current Beginning Cash Position is CHF186.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (XSWX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of CHF7.24 is trading 180.7% above its estimated GF Value™ of CHF2.58.

Key valuation signals for XSWX:NVAX:

  • Beginning Cash Position: CHF186.2 Mil
  • GF Value™: CHF2.58 vs. price of CHF7.24 (180.7% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the XSWX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
46GF Score

Get the complete analysis for XSWX:NVAX

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF7.24
Price
CHF2.58
GF Value